Paraganglioma (Glomus Jugulare Tumor) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Paraganglioma (Glomus Jugulare Tumor) – Drugs In Development, 2024 report and make more profitable business decisions.
Abnormal growth of chromaffin cells, a type of nerve cell found throughout the body leads to paraganglioma also known as glomus jugulare tumor. It is a rare form of neuroendocrine tumor. These tumors can be found in adrenal glands or outside of it especially in carotid artery. Cause is idiopathic. Headache, high blood pressure, faster pulse rate, sweating is some of the commonly seen symptoms. Paragangliomas can be either malignant or benign in nature and genetic mutations are believed to be one of the causes. Diagnosed by physical examination, urine test, blood catecholamine test, PET scan and other radiographic tests. If malignant only preventive or symptomatic care provided majorly beta-blockers if blood pressure is high. If cancerous chemo followed by radiation surgical procedure to remove the tumor.
The Paraganglioma (Glomus Jugulare Tumor) drugs in development market research report provide comprehensive information on the therapeutics under development for Paraganglioma (Glomus Jugulare Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Paraganglioma (Glomus Jugulare Tumor) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Paraganglioma (Glomus Jugulare Tumor) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Paraganglioma (Glomus Jugulare Tumor) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Paraganglioma (Glomus Jugulare Tumor) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Paraganglioma (Glomus Jugulare Tumor) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advanced Accelerator Applications SAAriceum Therapeutics GmbH
AstraZeneca Plc
Chimerix Inc
Enterome Bioscience SA
Exelixis Inc
Fukushima Medical University
Ipsen SA
Jubilant DraxImage Inc
Merck & Co Inc
Perspective Therapeutics Inc
Pfizer Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Paraganglioma (Glomus Jugulare Tumor) reports